SSKN Stock Overview
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
STRATA Skin Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.41 |
| 52 Week High | US$1.10 |
| 52 Week Low | US$0.26 |
| Beta | 1.6 |
| 1 Month Change | -17.76% |
| 3 Month Change | -22.58% |
| 1 Year Change | -60.54% |
| 3 Year Change | -72.46% |
| 5 Year Change | -82.61% |
| Change since IPO | -99.89% |
Recent News & Updates
Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt In A Risky Way?
Mar 19
STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Dec 31Recent updates
Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt In A Risky Way?
Mar 19STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Dec 31Health Check: How Prudently Does STRATA Skin Sciences (NASDAQ:SSKN) Use Debt?
Nov 03We Think STRATA Skin Sciences (NASDAQ:SSKN) Has A Fair Chunk Of Debt
Jul 04STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Stock Rockets 26% But Many Are Still Ignoring The Company
Apr 18Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?
Jan 14STRATA Skin Sciences GAAP EPS of -$0.05 in-line, revenue of $9.1M beats by $0.96M
Aug 10Strata Skin stock soars ~18% after hours on U.S. commercial launch of acne treatment
Jul 25What Type Of Returns Would STRATA Skin Sciences'(NASDAQ:SSKN) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Mar 09Reflecting on STRATA Skin Sciences' (NASDAQ:SSKN) Share Price Returns Over The Last Five Years
Nov 24
STRATA Skin Sciences EPS in-line, beats on revenue
Nov 10Shareholder Returns
| SSKN | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.1% | -0.5% | 1.6% |
| 1Y | -60.5% | -1.0% | 25.1% |
Return vs Industry: SSKN underperformed the US Medical Equipment industry which returned -1% over the past year.
Return vs Market: SSKN underperformed the US Market which returned 25.1% over the past year.
Price Volatility
| SSKN volatility | |
|---|---|
| SSKN Average Weekly Movement | 11.2% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SSKN's share price has been volatile over the past 3 months.
Volatility Over Time: SSKN's weekly volatility has decreased from 16% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 99 | Dolev Rafaeli | www.strataskinsciences.com |
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions.
STRATA Skin Sciences, Inc. Fundamentals Summary
| SSKN fundamental statistics | |
|---|---|
| Market cap | US$14.39m |
| Earnings (TTM) | -US$10.83m |
| Revenue (TTM) | US$33.36m |
0.4x
P/S Ratio-1.3x
P/E RatioIs SSKN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SSKN income statement (TTM) | |
|---|---|
| Revenue | US$33.36m |
| Cost of Revenue | US$14.90m |
| Gross Profit | US$18.46m |
| Other Expenses | US$29.29m |
| Earnings | -US$10.83m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 55.34% |
| Net Profit Margin | -32.47% |
| Debt/Equity Ratio | 118.6% |
How did SSKN perform over the long term?
See historical performance and comparison